Head-to-head comparisons of medication uses, side effects, warnings, and more.
Key takeaways
Januvia (sitagliptin) and Onglyza (saxagliptin) are both medications used to treat Type 2 diabetes and belong to the same drug class, dipeptidyl peptidase-4 (DPP-4) inhibitors. Januvia is a brand-name medication, while Onglyza is only available in its generic form, saxagliptin. The typical dose for Januvia is 100 mg once daily, whereas saxagliptin is taken at 2.5 mg or 5 mg once daily. Both medications can be taken with or without food. Januvia is not known to affect body weight, while saxagliptin has a low potential for causing weight gain. Common side effects of Januvia include runny nose and sore throat, while saxagliptin may cause upper respiratory tract infections and urinary tract infections. Both medications carry risks of serious side effects like pancreatitis and heart failure, but saxagliptin has a noted risk of causing severe joint pain and large blisters.
Januvia (sitagliptin)
Saxagliptin (Onglyza)
Januvia (sitagliptin)
Saxagliptin (Onglyza)
Summary of Januvia vs. Onglyza
Summary for DDP-4 inhibitor
Prescription only
Januvia (sitagliptin) is a prescription medication used along with a healthy diet and exercise to treat Type 2 diabetes. It belongs to the drug class dipeptidyl peptidase-4 (DPP-4) inhibitor, also known as gliptins. Januvia (sitagliptin) is taken by mouth, typically once daily. Most people don't experience many side effects from this medication, but possible ones include stuffy or runny nose, sore throat, and headache.
Summary for DPP-4 inhibitor
Prescription only
Saxagliptin (Onglyza) is an add-on medication to exercise and a balanced, nutritious diet to improve blood sugar control in adults with Type 2 diabetes. It belongs to the drug class called dipeptidyl peptidase-4 (DPP-4) inhibitors. The saxagliptin (Onglyza) dosage is taken by mouth once daily. Possible side effects include certain infections and headaches. The brand name, Onglyza, is no longer available. But the lower-cost generic version is still available.